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Abstract 
Because of the inflammatory mechanisms of most chronic upper airway diseases such as rhinitis and chronic rhinosi‑
nusitis, systemic steroids have been used for their treatment for decades. However, it has been very well documented 
that—potentially severe—side‑effects can occur with the accumulation of systemic steroid courses over the years. 
A consensus document summarizing the benefits of systemic steroids for each upper airway disease type, as well 
as highlighting the potential harms of this treatment is currently lacking. Therefore, a panel of international experts 
in the field of Rhinology reviewed the available literature with the aim of providing recommendations for the use of 
systemic steroids in treating upper airway disease.
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Introduction
Chronic upper airway inflammation is one of the most 
prevalent chronic disease entities in the world with rhi-
nitis being the most common presentation form affecting 
30% of the Western population [1].
Rhinitis is defined as an inflammation of the lining of 
the nose and is characterized by nasal symptoms includ-
ing rhinorrhoea, sneezing, nasal blockage and/or itch-
ing of the nose. Allergic rhinitis (AR) is the best-known 
form of non-infectious rhinitis and is associated with an 
IgE-mediated immune response against allergens [1]. 
However, a substantial group of rhinitis patients has no 
known allergy and they form a very heterogeneous non-
allergic rhinitis (NAR) patient population suffering from 
drug-induced rhinitis, occupational rhinitis, irritant-
induced rhinitis, hormonally linked rhinitis and idiopathic 
rhinitis [2, 3]. When inflammation of the nasal mucosa 
extends to the mucosa of the paranasal sinuses, the con-
sensus term of rhinosinusitis is used. Rhinosinusitis has 
been shown to affect about 10% of the Western popula-
tion [4]. In addition to rhinitis symptoms, rhinosinusitis 
is characterized by postnasal drip, facial pressure and 
reduction or loss of smell [5]. Acute rhinosinusitis (ARS) 
is a very common condition and mostly of viral origin [5]. 
About 0.5–2% of the viral ARS are complicated by a bac-
terial infection [5].
Chronic rhinosinusitis (CRS) is defined as the pres-
ence of two or more nasal symptoms, one of which 
should be either nasal blockage or nasal discharge, and/
or smell problems, and/or facial pain for more than 
12 weeks, in combination with inflammatory signs con-
firmed by nasal endoscopy and/or CT scan. CRS can 
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either present with nasal polyps (CRSwNP) or without 
(CRSsNP). Additionally, chronic upper airway disease 
often coexists with lower airway problems, most fre-
quently asthma, but also a link with chronic obstruc-
tive pulmonary disease (COPD) and bronchiectasis has 
been reported [6].
Glucocorticosteroids (GCS) are the oldest and most 
widely used anti-inflammatory therapy. Since their 
introduction in the 1950s, GCS have played a key role 
in the treatment of various inflammatory, allergic, and 
immunologic disorders. Consequently, they are known 
as a very effective drug for treating chronic airway 
inflammatory diseases involving both lower as well as 
upper airways [1, 4, 7]. GCS can be administered topi-
cal or systemically. If possible topical GCS are preferred 
over systemic GCS treatment as it is well known that 
this systemic GCS treatment is linked to an extensive 
range of potential adverse effects (AE’s) that have been 
well-described in the literature and vary from uncom-
fortable to life-threatening [8]. Notably, reports on AE 
and/or toxicity of systemic GCS cover a heterogeneous 
group of GCS-treated diseases, which complicates the 
interpretation of the actual risk for the rhinitis/rhinosi-
nusitis patients.
Therefore, the risk–benefit ratio of treating non-life-
threatening upper airway diseases with systemic GCS 
remains debatable and needs clarification.
This document summarizes the current evidence for 
beneficial as well as harmful effects of administration 
of systemic GCS in the different types of upper airway 
disease and aims at providing recommendations about 
its use in rhinitis and rhinosinusitis based on the cur-
rent evidence. For each topic 2 experts in the field were 
appointed to review the literature and topics that were 
appropriate for clinical recommendations were consid-
ered as evidence-based reviews with recommendations. 
The experts then provided a recommendation based 
upon the guidelines of the American Academy of Pedi-
atrics (following the recommendation strategy used by 
the International Consensus on Allergy and Rhinology 
[9]). Table  1 summarizes the recommendation devel-
opment based on the combination between levels of 
evidence and the benefit/harm balance. Generally, the 
search was focused on adults. Two experts reviewed 
the literature specifically for the pediatric population.
The search was performed in the MEDLINE (Ovid 
1946—current; and PubMed 1966—current) and 
Cochrane databases. The search strategy was based on a 
combination of MeSH-terms and free text words. Search 
terms are listed in Additional file 1.
Mechanisms and actions of GCS
Corticosteroids, which are produced by the adrenal 
glands, can be classified as glucocorticoids and mineralo-
corticoids. Cortisol is the endogenous glucocorticoid in 
humans, naturally derived from cholesterol metabolism 
upon stimulation by the hypothalamic–pituitary–adrenal 
axis (Fig. 1), which is regulated initially by the circadian 
rhythm, but also by negative feedback by glucocorticoids 
and glucocorticoid increment induced by stressors such 
as pain, inflammation or infections [10].
GCS are involved in several physiologic functions. They 
control the metabolism of carbohydrates, proteins and 
lipids, as well as the balance of calcium [11, 12]. However, 
the most explored effects of GCS are the anti-inflamma-
tory and immune-suppressive functions. GCS inhibit the 
activation and survival of inflammatory cells and modu-
late the activity of structural cells [13, 14]. The main anti-
inflammatory effects of GCS are based on their ability 
to reduce the synthesis of several cytokines (IL-1, -2, -3, 
-4, -5, -6, -8, TNF-α, IFN-γ, GM-CSF) from many cells 
(macrophages, monocytes, lymphocytes, fibroblasts, and 
epithelial and endothelial cells). This affects recruitment, 
localization, protein synthesis, and survival of inflam-
matory cells such as eosinophils [15]. The recruitment 
of inflammatory cells is also diminished by an inhibited 
expression of adhesion molecules such as ICAM-1 and 
VCAM-1 [16], which affects the influx of basophils and 
mast cells in the epithelial layers of nasal mucosa. Finally, 
GCS are involved in the pathological wound repair 
mechanism called remodelling. Remodelled tissue such 
as the stroma of nasal polyps contains abundant infiltra-
tion of inflammatory cells, increased fibroblasts numbers 
and increased extra-cellular matrix deposition. However, 
Table 1 American Academy of Pediatrics defined strategy for recommendation development [9]
RCT randomized controlled trial
Evidence quality Preponderance 
of benefit over harm
Balance of benefit 
and harm
Preponderance of harm 
over benefit
A. Well‑designed RCTs Strong recommendation Option Strong recommendation 
againstB. RCT’s with minor limitations; overwhelming consistent evi‑
dence from observational studies
Recommendation
C. Observational studies (case–control and cohort design) Recommendation against
D. Expert opinion; case reports; reasoning from first principles Option No recommendation
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GCS appear to be minimally effective in reversing the 
structural changes resulting from remodelling [17].
All these effects are exerted by intracellular activa-
tion of the glucocorticoid receptor (GR) [18]. The GR 
belongs to the superfamily of ligand regulated nuclear 
receptors [19] and alternative splicing of the GR primary 
transcript generates two receptor isoforms, named GRα 
and GRβ. GRα has a widespread distribution in cells and 
tissues [20], including healthy and diseased upper airway 
mucosa. Inactive GRα is found primarily in the cytoplasm 
of cells as part of a large multi-protein complex [21]. Glu-
cocorticoids diffuse across the cell membrane and bind to 
GRα resulting in a nuclear entry (Fig. 2) [22] where GRβ 
modulates either positively or negatively the expression 
of target genes. GRβ has a very low level of expression 
Fig. 1 The hypothalamic–pituitary–adrenal axis. Stress stimuli induce the production of CRH by the hypothalamus. CRH induces the production of 
ACTH by the pituitary gland which stimulates the production of glucocorticoids (cortisol) in the adrenal gland cortex. Cortisol acts on many cells, 
tissues, and organs including the immune system. The excessive release of cortisol as well as proinflammatory cytokines have a negative feedback 
on the central nervous system by inhibiting this circadian cycle. CRH corticotrophin releasing hormone, ACTH adrenocorticotrophin hormone
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compared to GRα [20] and acts mainly as a negative 
inhibitor of GRα-mediated gene modulation [23].
The anti-inflammatory effects of GCS are explained 
by three broad molecular mechanisms: the decreased 
expression of pro-inflammatory genes (trans-repression), 
the increased expression of anti-inflammatory genes 
(trans-activation), and non-genomic mechanisms. Trans-
repression is thought to be mainly due to direct interac-
tions between GRα and pro-inflammatory transcription 
factors such as the activator protein-1 (AP-1) and NF-κB 
[24]. Trans-activation is explained by the interaction of 
GRα to specific target DNA sequences, named gluco-
corticoid-responsive elements (GRE). Among the genes 
activated by GRα through GRE with anti-inflammatory 
functions, there are the mitogen activated protein kinase 
phosphatase-1, the glucocorticoid inducible leucine zip-
per and tristetraprolin. In addition, the activated GRα 
can also reduce inflammation at the post-transcriptional 
(altering mRNA stability), translational (affecting protein 
synthesis) and post-translational levels (altering protein 
processing, modification or degradation) (Fig.  2). For 
example, the expression of cyclooxygenase-2, TNF-α 
and GM-CSF are regulated by one or more of these post-
genomic mechanisms [25].
Increased expression of GRβ has been reported in dif-
ferent inflammatory diseases, including asthma, and 
nasal polyposis and has been proposed as one of the 
potential mechanisms explaining GC resistance [26]. The 
expression of GRβ is higher in nasal polyps than in nasal 
mucosa epithelial cells and correlates with increased 
infiltration of inflammatory cells [27]. Although down-
regulation of GRα after treatment with glucocorticoids 
has been reported [28] and could account for secondary 
steroid resistance, a recent study in patients in patients 
with nasal polyps has shown that this effect does not 
occur in vivo [29].
Evidence for efficacy of systemic GCS in different 
inflammatory upper airway diseases
1. Allergic rhinitis
AR is the most prevalent presentation form of all allergic 
diseases and the most com-mon chronic disorder in chil-
dren. It is considered a risk factor for the development 
of asthma and a major public health problem, due to its 
Fig. 2 Molecular mechanisms of glucocorticoid action. After crossing the cell membrane by passive diffusion, glucocorticoids bind to GRα, 
associated heat‑shock proteins (HSP) are released, and the ligand bound receptor translocates into the nucleus. Through the activation of MAP 
kinase (MAPKs) intracellular cascade, inflammatory stimuli induce the production of transcription factors. A GRα dimer can bind glucocorticoid 
responsive elements (GRE) on the promoter region of target genes and activate anti‑inflammatory gene (MKP‑1, GILZ, TTP, lipocortin‑1) 
transcription. B Binding of GRα to a negative GRE (nGRE) leads to gene (POMC, osteocalcin) repression. C Protein–protein interactions between 
GRα and transcription factors (AP‑1, NF‑κB) repress the transcription of pro‑inflammatory genes (COX‑2, TNF‑α, VEGF, IL‑8). D GRα can alter mRNA or 
protein stability of inflammatory mediators
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prevalence and impact on patients’ quality of life, work/
school performance, and economic burden [30].
Intranasal GCS and oral/topical antihistamines are the 
most effective symptomatic treatment for AR and should 
be the first-line therapy for mild to moderate disease [30, 
31]. Moderate to severe disease not responsive to intra-
nasal GCS, should be treated with additional pharmaco-
logical therapies (including cromolyns and leukotriene 
receptor antagonists), allergen immunotherapy (AIT) 
and non-pharmacologic therapies (such as nasal irriga-
tion) [30, 31]. Usually a combination of intranasal GCS 
and a topical or oral antihistamine is used for moderate 
to severe AR.
Regarding the use of systemic GCS in AR, the current 
evidence is scarce. Three studies compared the effect of 
systemic GCS in adult patients (> 15  year old) with AR 
(Table 2).
The first randomized controlled trial (RCT) from 1987 
showed a beneficial effect of a depot injection of 80 mg 
methylprednisolone (MP) vs. placebo on nasal obstruc-
tion and eye symptoms in 48 AR patients, which lasted 
for 4 weeks [32]. The second study by Brooks et al. [33] 
investigated the efficacy of different doses of oral MP 
and placebo in patients not treated with other medica-
tions. Thirty-one patients were randomized to receive 
0, 6, 12, or 24 mg MP. Oral GCS produced dose-related 
reduction in all symptoms. The difference between pla-
cebo and 24 mg MP was significant for all the symptoms 
monitored, except itching, which benefited marginally. 
With 6 mg MP, congestion, drainage, and eye symptoms 
showed significant drug-placebo differences, but itching, 
running/blowing, and sneezing did not. The third study 
by Laursen et  al. [34] compared prednisone 7.5  mg for 
3  weeks with a single intramuscular injection of beta-
methasone dipropionate also in patients not treated with 
other medications. This study showed a therapeutic index 
in favour of the depot injection versus oral treatment in 
AR [33].
Despite the therapeutic benefits of systemic GCS in 
the treatment of AR that were shown in these studies, 
their use is strongly recommended against in view of the 
AE’s GCS that are discussed below, and a short course 
of systemic GCS is only indicated in rare cases. These 
cases include patients with severe symptoms who do not 
respond to other drugs, or those who are intolerant to 
intranasal drugs [1, 35]. Systemic GCS should never be 
considered as a first-line of treatment for AR [1]. Con-
sequently, oral GCS can be used for a few days as in 
carefully selected cases when other medical treatment 
options have failed.
• Evidence level: B.
• Benefits–harm assessment: AE’s of systemic GCS 
outweigh advantages of therapeutic value, except 
for patients suffering from very severe and therapy-
resistant symptoms.
• Recommendation: Strong recommendation against. 
Option in patients suffering from very severe and 
therapy-resistant symptoms.
2. Non‑allergic rhinitis
Although, the prevalence of NAR among the chronic 
rhinitis patients ranges from 20 to 50% [36], their dis-
ease mechanisms and treatment options are much less 
studied than their allergic peers. NAR comprises a het-
erogeneous group of chronic rhinitis subtypes, such as 
drug-induced rhinitis, hormonal-induced rhinitis, some 
forms of occupational rhinitis and rhinitis linked to sys-
temic diseases [37]. However, in about 50% of the NAR 
patients, no specific causal factor can be found and this is 
addressed as idiopathic rhinitis (IR) [37]. Up till now, no 
studies are available that investigate the effectiveness of 
systemic steroids in NAR or IR patients. However, since 
it is believed that in IR neurogenic pathways are involved, 
rather than classical inflammatory pathways [38], sys-
temic GCS are not the therapy of choice. Of note, all IR 
patients included in a recent study investigating the effect 
of capsaicin in IR, reported lack of clinical response to 
intranasal GCS [38]. By extrapolation, there is a low like-
lihood of oral GCS being effective in this patient popu-
lation, unless more than one etiologic or inflammatory 
mechanism underlies the development of rhinitis.
Only in selected cases of other subtypes of NAR, such 
as rhinitis linked to vasculitic or systemic diseases, oral 
GCS might play a role in the treatment strategy (see 
below) [39]. Although oral GCS are often prescribed in 
patients suffering from rhinitis medicamentosa to over-
come the withdrawal period of topical decongestants, 
there are no valuable studies supporting this clinical 
practice.
• Evidence level: D.
• Benefits–harm assessment: AE’s of systemic GCS 
outweigh advantages of therapeutic value.
• Recommendation: Recommendation against.
3. Acute rhinosinusitis
Compared to the literature on effectiveness of systemic 
GCS in CRS, data on acute rhinosinusitis (ARS) are 
scarce. In 2014 an update of a Cochrane review was pub-
lished [40] concluding that systemic GCS as a monother-
apy are ineffective compared to placebo in ARS patients, 
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but might have a beneficial effect on short-term symptom 
relief when used as an adjunctive therapy to antibiotics.
Up to date, five randomized, placebo-controlled trials 
investigating the effect of oral GCS in adults with ARS 
are available and included in the Cochrane meta-analysis 
(Table 3). From those, only one focused on systemic GCS 
as a monotherapy [41]. In this high-quality second-line 
clinical trial, patients with clinically diagnosed ARS were 
randomized to receive either prednisolone 30 mg/day or 
placebo for 7  days. In the 174 patients who completed 
the trial, no clinically relevant benefit of prednisolone 
over placebo was found regarding facial pain or pressure, 
other nasal symptoms or quality of life.
Four other RCTs investigated the adjunctive effect of 
systemic GCS to oral antibiotics in ARS. Gehanno et al. 
[42] reported the adjuvant effect of 5  days of 3 × 8  mg 
MP/day to amoxicillin–clavulanate in 417 patients. On 
day four, patients showed significantly less pain in the 
steroid group whereas nasal discharge did not signifi-
cantly improve. The use of additional medication was not 
reported.
In 2004, two similar studies were published; a French 
study [43] showed a beneficial effect on pain with oral 
prednisone as an add-on therapy to cefpodoxime in 291 
ARS patients. Also Ratau et al. [44] reported a significant 
benefit of 1 mg of oral betamethasone per day as adjunct 
to amoxicillin–clavulanate in 42 patients.
In 1990 Cannoni already published similar findings 
showing a better symptom resolution in ARS patients 
treated with 40  mg prednisolone/day in combination 
with antibiotics, compared to patients receiving a non-
steroidal anti-inflammatory drug (NSAID) with antibiot-
ics [45].
Altogether, these limited data suggest that systemic 
GCS as a monotherapy appear to be ineffective in ARS 
patients. However, oral GCS in combination with antibi-
otics may be modestly beneficial for short-time symptom 
relief in adults suffering from ARS, compared to antibiot-
ics alone, with a number needed to treat of seven [40]. 
Due to the small number of included studies (n = 5) and 
their methodological bias, a definite conclusion would 
only be justified if large controlled trials would be avail-
able. Given the self-limiting nature of ARS, the rela-
tively small additional clinical benefit of adding GCS to 
antibiotics, and the potential AE’s, GCS should not be 
used routinely, but may be considered an option after 
informed discussion and shared decision making with 
the patient in the setting of severe pain.
• Evidence level: B.
• Benefits–harm assessment: AE’s of systemic GCS 
outweigh advantages of therapeutic value in mild and 
moderate disease.
• Recommendation: Strong recommendation against 
when only mild to moderate symptoms. Option in 
patients suffering from severe headaches/symp-
toms when combined with antibiotics.
4. Chronic rhinosinusitis without nasal polyps
For clinical purposes, the definition of CRS includes 
nasal polyposis (NP) and currently it is still unclear 
why some CRS patients develop NP and others do 
not. CRSsNP is characterized by basement membrane 
thickening, goblet cell hyperplasia, fibrosis, subepithe-
lial oedema and influx of inflammatory cells that are 
mainly of the neutrophilic subtype with a cytokine pat-
tern deviated towards the Th1 subtype [5].
Based on available data, medical therapy for CRS 
should begin with daily application of intranasal ster-
oids in conjunction with saline irrigation and subse-
quent therapies are based on the patient’s severity of 
symptoms and/or quality of life impairment [4].
There is limited data showing efficacy of oral GCS in 
CRSsNP and a systematic review analysed the available 
literature in 2011 [46].
No RCT investigated the effects of oral GCS in 
CRSsNP and only two retrospective case series in 
adults are available [47, 48] that both considered 
CRSwNP and CRSsNP patients, but sub-group analy-
sis allowed an evaluation specific to CRSsNP (Table 4). 
Both retrospective studies investigated the effects of 
oral prednisone in conjunction with 1  month of oral 
antibiotics added to intranasal steroids and irrigations. 
Improved subjective and objective outcomes were seen 
after multimodality treatment schemes in both stud-
ies for CRSsNP. The study of Subramamian et  al. [48] 
pooled both CRSwNP and CRSsNP patients and found 
that the CRSsNP patients had better outcomes than 
CRSwNP patients. Lal et  al. [47] demonstrated that 
the CRSsNP patients showed total symptom resolution 
2 months after treatment of 54.9% compared to 51% for 
the total CRS group. There are no studies available that 
investigated the benefits of systemic GCS in monother-
apy in treating CRSsNP.
Because of a lack of RCTs or even prospective stud-
ies, evidence for clinical efficacy of oral GCS therapy in 
CRSsNP is Level 4 or 5 and in view of the AE discussed 
later on, not recommended for the management of 
CRSsNP.
• Evidence level: C.
• Benefits–harm assessment: AE’s of systemic GCS 
outweigh advantages of therapeutic value.
• Recommendation: Recommendation against.
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5. Chronic rhinosinusitis with nasal polyps
CRSwNP is different from CRSsNP by the presence of 
nasal polyps consisting of a large quantity of extracellular 
oedema with the presence of a dense inflammatory cell 
infiltrate [49, 50], which is characterized in about 80% of 
the Caucasian CRSwNP patients, by activated eosino-
phils [51, 52] and is associated with a predominant Th2 
cytokine profile (IL-4, IL-5, IL-10, eotaxin) [53, 54].
A recent suite of Cochrane Reviews has considered the 
efficacy of interventions for CRSwNP. Two reviews were 
performed with respect to short-term oral GCS; one 
comparing oral GCS alone versus placebo or other treat-
ment [55], and a second comparing oral GCS used as an 
adjunct to other treatments, versus control [56].
For oral GCS alone, 8 trials with a total of 474 partici-
pants, all of whom were adult patients CRSwNP, were 
identified [57–64]. All studies followed up patients to the 
end of the treatment course, and 3 followed patients for 
3 to 6  months after completion. Patients receiving oral 
GCS achieved better quality of life (standardized mean 
difference (SMD) of − 1.24 95% CI − 1.92 to − 0.56, 
measured with RSOM-31), lower nasal symptom scores 
(SMD − 2.84, 95% CI − 4.09 to − 1.59) and greater polyp 
reduction (SMD − 1.21) than control groups at the end 
of the course of treatment. However, there was no differ-
ence between groups at 3 to 6 months after the course of 
treatment.
Treatment doses utilized in included studies included 
prednisone at 30  mg and reduced over 14  days, pred-
nisolone at 60  mg reducing over 17  days, or at con-
stant dosage of 50 mg or 25 mg for 14 days, or reducing 
dosages of MP over 20  days. Of the three studies that 
followed patients beyond the course of treatment, 2 
prescribed ongoing intranasal GCS after completion of 
the systemic dose to both groups while one did not [58, 
62, 63].
Included trials were considered to be at low risk of 
bias, but overall the quality of evidence was rated as 
low due to the small numbers of participants, heteroge-
neity of outcome measures and limited follow-up time 
in most studies.
Another trial considered oral GCS versus placebo as 
an adjunct to treatment with intranasal GCS in CRSwNP 
patients [65]. This study recruited 30 participants and 
was considered at high risk of bias because of lack of 
blinding and lack of information on randomization. It 
reported greater reduction in polyp size in the active 
treatment arm (MD − 0.46, 95% CI − 0.87 to − 0.05).
One trial included in the Cochrane review of oral 
GCS as an adjunctive treatment recruited children [66] 
and is therefore considered later in this document.
Table  5 summarizes the evidence of these stud-
ies and provides a recommendation for the treatment 
of CRSwNP by systemic GCS. There is good evidence 
that systemic GCS are effective in the management of 
CRSwNP, at least in the short-term. However, consid-
ering the evolving understanding of CRSwNP and the 
chronicity of this condition, the short-lived benefits of 
systemic GCS therapy need to be balanced with the long-
term potential AE’s which are discussed below. Therefore, 
systemic GCS should not be considered as a first line 
of treatment for CRSwNP. They can be used in a short 
course during 2–3  weeks as a last resort of treatment 
when combinations of other medications are ineffective. 
Table 4 Summary of the evidence for ‘efficacy of systemic steroids in CRSsNP in adults’
CRS chronic rhinosinusitis, CRSsNP chronic rhinosinusitis without nasal polyps, CRSwNP chronic rhinosinusitis with nasal polyps
Study Year LOE (1a to 5) Study design Study groups Clinical end‑point efficacy Conclusion
Subramanian et al. 2002 4 Retrospective CRS patients (23 CRSsNP 
and 17 CRSwNP) treated 
with 1 month antibiot‑
ics + intranasal ster‑
oids + prednisone tapered 
over 10 days (20 mg 2×/
day for 5 days, 20 mg 1×/
day for 5 days). Mostly 
adult patients (2 patients 
under 18)
Change in CT scores, symp‑
tom scores post‑treatment. 
Time to relapse
Beneficial effect of multimodal 
therapy on scoring of CT, 
symptoms or both in 90% of 
all CRS patients, no specific 
subanalysis for CRSsNP. 
Beneficial effect continued 
beyond 8 weeks in 60% of 
patients. No subanalysis 
made for CRSsNP
Lal et al. 2009 4 Retrospective Adult CRS patients (23 
CRSsNP and 17 CRSwNP) 
treated with antibiot‑
ics + intranasal ster‑
oids + intranasal decon‑
gestants + prednisone 
tapered over 12 days (60, 
40, 20, 10 mg for 3 days 
each)
Complete endoscopic and 
symptomatic resolution of 
symptoms 2 months after 
start of treatment
Beneficial effect of treatment 
in 54.9% of CRSsNP
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• Evidence level: A.
• Benefits–harm assessment: AE’s of systemic GCS 
outweigh advantages of therapeutic value in the long-
term, except in patients with severe symptomatology.
• Recommendation: Strong recommendation against. 
Option for a short-term course in patients with 
severe symptoms and therapy-resistance.
A separate indication, for which oral GCS have been 
prescribed in CRSwNP patients, is the preoperative 
setting, in order to reduce perioperative bleeding and 
improve surgical conditions for the surgeon during endo-
scopic sinus surgery (ESS). Of the five studies that have 
been performed studying this topic in adults (Table  6), 
four are RCTs, however, their outcomes are not con-
clusive The study from Ecevit demonstrated a signifi-
cant improvement on all perioperative variables studied 
(perioperative bleeding, visibility of the operative field, 
operative time, hospital stay) after a preoperative course 
of GCS in CRSwNP patients [59]. However, while some 
other studies confirm a significant improvement of intra-
operative bleeding time [67] or quality of the operating 
field [68] and surgical time [69], these differences were 
not found to be significant by their colleagues [67–70]. A 
recent meta-analysis reported on a significant reduction 
in operating time, perioperative blood loss and improved 
surgical field quality when patients were given preopera-
tive steroid treatment, however, the result was mainly 
based on a large RCT reporting on intranasal GCS [71]. 
Therefore, the use of oral GCS is currently not recom-
mended in the preoperative setting of CRSwNP patients.
• Evidence level: B.
• Benefits–harm assessment: AE’s of systemic GCS 
outweigh advantages of therapeutic value.
• Recommendation: Strong recommendation against.
6. Allergic fungal rhinosinusitis
Allergic fungal rhinosinusitis (AFRS) is a form of a non-
invasive fungal rhinosinusitis and although it is not 
characterized by a specific phenotype, it seems to be an 
immunologically distinct subtype of CRS [72]. The diag-
nosis is based on the criteria proposed by Bent and Kuhn: 
(1) production of eosinophilic mucin without fungal 
invasion into sinonasal tissue; (2) positive fungal stain of 
sinus contents; (3) nasal polyposis; (4) characteristic radi-
ographic findings; and (5) allergy to fungi [73]. In view of 
the locally aggressive character of the disease, the corner-
stone of AFRS treatment is surgery [74]. However, a lot 
of uncertainty remains concerning the medical options 
and postoperative therapy. Although no RCTs are avail-
able, we found four smaller studies that investigated 
the role of GCS in the management of AFRS mostly in 
adults (Table 7). Two prospective non-controlled studies 
examined the effects of GCS in a small number of AFRS 
patients without surgery [75, 76]. Woodworth showed 
a significant reduction in nasal endoscopy scores and 
inflammatory markers in the AFRS group after 18  days 
of prednisone [76]. Landsberg [75] showed a more sig-
nificant reduction in radiologic and mucosal scoring 
in AFRS patients compared to CRSwNP patients after 
10  days of prednisolone. An older retrospective study 
from Kupferberg [77] in 26 AFRS patients, found that 
patients who received postoperative GCS showed more 
symptom improvement and less endoscopic disease com-
pared to treatment with oral antifungals or no treatment. 
However, disease recurrence was noted after cessation of 
GCS. Similar findings were seen in a non-controlled ret-
rospective study from Kuhn and Javer [78] who showed a 
maintenance of low endoscopic scores in AFRS patients, 
only after long-term GCS use. No AE’s were reported in 
any of the four studies. It has to be noted that all of these 
studies have a high risk of bias and the level of evidence 
for the use of oral GCS in AFRS patients remains at level 
C.
• Evidence level: C.
• Benefits–harm assessment: Balance of harm and 
benefit in patients with severe disease.
• Recommendation: Option in patients with severe 
AFRS (severe symptoms and/or locally invasive dis-
ease) in conjunction with ESS.
7. Nasal manifestations of auto‑immune disease
Many auto-immune disorders can involve the nose: 
thyroid auto-immunity, various vasculitis, Sjogren’s 
syndrome and sarcoidosis are the most frequently 
encountered, but other connective tissue diseases, such 
as systemic lupus erythematosus, polyarteritis nodosa, 
scleroderma and relapsing polychondritis can also have 
nasal symptoms [39].
GCS have been the major therapeutic option for some 
of these diseases as an immune suppressant for the past 
decades, probably being most effective where eosino-
phils, which are exquisitely steroid-sensitive, are involved 
[79]. However, the quality of the evidence for their effi-
cacy is poor, with studies mostly being reviews or open 
pilots, even in seminal trials such as those of Fauci for 
Wegener’s granulomatosis [80–82]. The reasons for this 
include not only time-hallowed use, but also difficulty 
in undertaking placebo-controlled trials in severe dis-
eases, differences in the manifestations and their inten-
sity between individual patients, disease complexity and 
plasticity and probably lack of interest in funding. This 
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situation is now changing with the advent of newer thera-
pies, particularly monoclonal antibodies, which are being 
trialled against older therapies including GCS [83].
Churg–Strauss syndrome, now called eosinophilic 
granulomatosis with polyangiitis (EGPA), is classically 
considered a Th2-mediated disease and affects sino-nasal 
mucosa in > 80% of the patients. Treatment must be tai-
lored according to prognostic factors identified by the 
French Vasculitis Study Group [84]. GCS alone are used 
for mild disease, high-dose GCS and cyclophosphamide 
is still the gold standard for severe cases [85], but biologi-
cal agents such as rituximab or anti-IL-5 biologicals are 
promising, though costly, alternatives [86].
The hallmark of granulomatosis with polyangiitis (GPA; 
previously known as Wegener’s disease) is the coexist-
ence of vasculitis and granuloma and again over 80% of 
patients show sino-nasal involvement [87]. GCS alone are 
insufficiently effective: the induction treatment for severe 
GPA comprises GCS combined with another immu-
nosuppressant, cyclophosphamide or rituximab. Once 
remission is achieved, maintenance strategy following 
cyclophosphamide-based induction relies on less toxic 
agents such as azathioprine or methotrexate.
GCS decrease the frequency, duration, and severity of 
flares in relapsing polychondritis, but do not stop disease 
progression in severe cases [88].
The presence of sino-nasal disease is associated with 
more severe sarcoidosis and the need for systemic GCS 
therapy [89].
Treatment for systemic lupus erythematosus (SLE) by 
various organ systems is not evidence-based beyond the 
usual first- or second-line treatment, however a recent 
meeting achieved consensus in several scenarios, includ-
ing anti-phospholipid syndrome [90].
GCS, often combined with NSAIDs, are used in 
Sjogren’s syndrome to treat associated interstitial lung 
disease and/or sensorineural hearing loss [91].
Table 8 shows the evidence available for auto-immune 
disorders for which GCS are frequently used.
• Evidence level: D.
• Benefits–harm assessment: Depending on other 
organ involvement and severity.
• Recommendation: Following the recommendation 
for the management of the specific auto-immune dis-
ease.
8. Sino‑nasal pathology and concomitant asthma
Asthma is a chronic inflammatory disease of the 
lower airways involving inflammation of the bronchial 
mucosa, and variable obstruction of bronchi due to 
intrinsic/extrinsic stimuli, and leading to symptoms 
such as episodic breathlessness and wheezing with air-
way hyperresponsiveness to environmental stimuli [92]. 
Since the introduction of the “United Airway Disease” 
concept [1], a large series of scientific publications 
from clinical epidemiology, pathophysiology, histology, 
and treatment outcomes has correlated asthma and 
upper airway disease. AR and asthma often coexist and 
AR is regarded as a risk factor for the development of 
asthma. Uncontrolled rhinitis impacts asthma control. 
Asthmatic patients have a higher CRS severity score 
than non-asthmatic patients, and more nasal polyps, 
indicative of a strong relationship between CRS sever-
ity and asthma [93]. It has been reported that 20–60% 
of patients with CRSwNP have asthma [94, 95].
The first use of GCS to treat acute asthma exacerba-
tion was in 1956 [96]. Development of GCS that have 
less mineralocorticoid activity, like prednisone, and 
later those that have no mineralocorticoid activity, like 
dexamethasone, made steroid use more attractive ther-
apies to use in asthma. Prescribing a short course of 
oral GCS following the treatment of acute asthma exac-
erbations was found to reduce the rate of relapse [97]. 
However, courses longer than 5 days were not found to 
provide any additional benefit [98].
As described above, systemic GCS should not be con-
sidered as a treatment for AR. We could not identify 
any systematic review, randomized trial, or controlled 
study that evaluated the use of systemic GCS in patients 
with AR with concomitant asthma not responding to 
other therapy.
When analysing the evidence of oral GCS for patients 
with CRS and coexisting asthma there are a few rand-
omized controlled trials and uncontrolled prospective 
interventional studies that evaluated the efficacy of dif-
ferent treatments (Table 9) of which only one looked at 
systemic GCS use. This study was carried out in adults 
by Ikeda et al. [99] and included 21 CRS patients with 
concomitant asthma. Fifteen patients underwent ESS, 
and 6 other patients remained on medical therapy. 
Seven patients of the ESS group showed a reduction in 
the need for GCS during the 6  months following sur-
gery, whereas two patients were unchanged and two 
patients required larger dosages.
Generally, due to a lack of studies investigating the 
efficacy of GCS in asthmatics with CRS, the same rules 
apply as for non-asthmatic CRS patients. With regards 
to the morbidity and potential mortality that is asso-
ciated with asthma, the use of GCS in asthmatic CRS 
patients should be directed in the first place by the 
severity of the lower airway symptoms.
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• Evidence level: D.
• Benefits–harm assessment: AE’s of systemic GCS 
outweigh advantages of therapeutic value in the long-
term, except in patients with severe symptomatology.
• Recommendation: Recommendation against. Option 
in patients with severe symptoms and therapy-resist-
ance.
Adverse effects of systemic GCS
Although GCS play a key role in the treatment of various 
inflammatory disorders, including chronic upper airway 
disease, a quite extensive range of potential AE’s is well-
described in literature and the chance to develop these 
effects seems to increase with higher dose and longer 
duration of treatment [8, 100–102].
However, few studies have actually addressed the risk 
of common GCS-induced AE in upper airway disease. 
Also, most of the studies available on GCS focus on high 
dose or long-term usage for at least 6  months or even 
1 year consecutively, which is mostly less relevant in the 
upper airway disease patient group.
In the following section, we aimed at summarizing the 
data of potential short- as well as long-term AE’s of sys-
temic GCS treatments for rhinitis and/or rhinosinusi-
tis in the adult population. Due to the heterogeneity in 
studies, treatment regimens and patient populations, we 
classified the side-effects according to the organ-system 
involved, but no further subdivision was made. When no 
studies were available for upper airway disease patients, a 
mention of studies investigating AE’s in similar patients 
(ophthalmologic, asthmatic) was made. Studies investi-
gating side-effects in children will be discussed separately 
in the next chapter.
1. Hypothalamic–pituitary–adrenal‑axis (HPA) inhibition
Reductions in the level of plasma cortisol are reported 
after one injection of GCS. They usually decrease in the 
first 2  weeks after steroid administration, but slowly 
return to normal after 3  weeks, as has been demon-
strated in patients with AR [103]. Hedner et  al. [104] 
showed a minor HPA dysfunction in 14 allergic patients 
treated with a single intra-muscular injection of MP 
acetate, which returned completely to normal at 4 weeks 
post-injection. In a double-blind study by Laursen et al. 
[105] 36 birch pollen allergic patients were treated with 
either a single injection of betamethasone dipropion-
ate or oral prednisolone 7.5  mg/day for 3  weeks. Only 
the prednisolone treated patients showed reduction in 
plasma cortisol levels at 3 weeks.
Bonfils et  al. [106] prospectively evaluated the HPA-
axis in patients with CRSwNP (n = 46), who received 
at least three short courses of oral GCS in the last year 
(course 6–8  days, 1  mg/kg/day, mean duration of treat-
ment 4.7 years, mean 6.8 courses/year, mean cumulative 
prednisone consumption 3,800  mg). The study demon-
strated that 48% of patients had an asymptomatic adrenal 
insufficiency diagnosed with the Synacthen test.
2. Hyperglycemia and diabetes
A retrospective study based on Danish National Regis-
tries, including 47,382 AR patients, demonstrated that 
treatment with at least one consecutive injection of depot 
corticosteroid for 3  years on a row was associated with 
an increased risk of being diagnosed with diabetes later 
in life (RR 1.4) [107]. The degree of new-onset diabetes 
associated with intermittent short-term oral GCS has not 
been clearly established.
3. Osteoporosis
In the same Danish epidemiological study, Aasbjerg et al. 
[107] showed that, compared to immunotherapy, treat-
ing AR with annual depot-steroid injections (i.e. at least 
one steroid injection in the pollen season for 3 consecu-
tive years) was associated with increased risk of being 
diagnosed with osteoporosis (RR 1.2). The above-men-
tioned study from Bonfils, investigating the HPA-axis, 
prospectively evaluated the occurrence of osteoporo-
sis in patients with CRSwNP (n = 46), receiving at least 
three short courses of oral GCS in the previous year. 
Osteopenia of the proximal femur was present in 40.5% 
and osteoporosis was present in 54% [106]. Rajeskaran 
et al. [108] retrospectively evaluated the risk of osteopo-
rosis in patients with CRS (n = 176), who received oral 
GCS ≥ 5  mg daily for 3  consecutive months any time 
in the past. Overall, low bone mineral densities (BMD; 
osteopenia or osteoporosis) was 38.6%. These studies 
were recently evaluated in a systematic review which was 
Table 9 Summary of the evidence for ‘efficacy of systemic steroids in sinonasal disease + concomitant asthma
RCT randomized controlled trial, CRS chronic rhinosinusitis, CRSsNP chronic rhinosinusitis without nasal polyps, CRS chronic rhinosinusitis, CRSwNP chronic 
rhinosinusitis with nasal polyps, GCS glucocorticosteroids
Study LOE (1a to 5) Study design Study groups Clinical endpoints efficacy Conclusion
Ikeda et al. [99] 3 Prospective RCT Adult CRSwNP and CRSsNP 
patients undergoing ESS
1. Sinonasal and pulmonary 
symptoms
2. Systemic GCS need
1. Improvement of  FEV1
2. No significant changes in 
systemic GCS need
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unfortunately not able to quantify the overall risk of oste-
oporosis induced by oral GCS for CRSwNP, due to the 
low number of studies [109].
The effects of short-course oral GCS on bone mineral 
density (BMD) have also been investigated in a 4-year 
longitudinal small study in asthmatic patients. Asthmatic 
patients receiving frequent short courses of oral GCS (i.e. 
> 2.5  courses/year; n = 9) compared to those receiving 
sporadic courses (i.e. ≤ 2.5 courses/year; n = 26) revealed 
a greater loss of lumbar BMD (T-score 82.0% versus 
T-score 77.7%) in the frequently treated group [110]. 
Also, a lower Z-score of 93.1% was demonstrated in fre-
quent short courses, versus the sporadic courses that did 
not show a lower Z-score than the normal population 
values (Z-score 100.1%).
4. Avascular necrosis
With regards to avascular necrosis of the femoral head 
in patients treated with systemic GCS for upper airway 
disease, we found 1 case report of Nasser et  al. [111] 
describing a single case with severe hay fever that was 
given at least one depot corticosteroid injection each year 
for 11 years, leading to avascular necrosis.
More individual case reports highlight the relationship 
between the use of systemic GCS and avascular necrosis. 
The risk to develop osteonecrosis seems to be dependent 
on the prescribed dose, the cumulative dose and route of 
administration, as well as underlying disease states (SLE 
patients seem to be particularly at risk) [112–114].
5. Gastrointestinal disturbances and peptic ulceration
In a randomized double-blind placebo-controlled study 
by Kirtsreesakul et  al. [62] 112 patients with CRSwNP 
used either 50 mg prednisone or placebo for 14 days and 
reported significantly more (mild) gastrointestinal distur-
bances and dyspepsia in the prednisolone treated group. 
In a double-blind placebo-controlled trial by Venekamp 
et  al. [41] 174 adult patients clinically diagnosed with 
ARS received either 30 mg/day prednisolone or placebo 
for 7  days. The incidence of gastrointestinal complaints 
did not differ between treatment groups.
In a large nested case–control analysis based on the UK 
General Practice Research Database, 2105 cases of upper 
gastro-intestinal complications were compared to 11,500 
controls and then evaluated for exposure to certain drugs 
e.g. corticosteroid use. The adjusted OR for current use 
of oral GCS was 1.8 (95% CI 1.3–2.4) for upper gastro-
intestinal complications overall [115]. No statistically sig-
nificant difference could be objectified for lower versus 
higher dosage of GCS. To our knowledge no studies in 
upper airway disease patients report on systemic steroid 
treatment and peptic ulceration.
6. Ocular adverse effects
GCS have been described to induce the formation of 
posterior subcapsular cataract or glaucoma. The risk 
for patients using repeated (short) courses of systemic 
GCS for upper airway disease is currently unknown.
There is evidence in rheumatoid arthritis patients 
that this risk is enhanced after therapy lasting more 
than 1  year [116]. Another study by Huscher et  al. 
[101] analysed dose-related patterns of self-reported 
symptoms from 1066 patients with RA with ongoing 
long-term (> 6  months) systemic GCS. These symp-
tom patterns were compared to non-users (no systemic 
GCS for at least 12  months). The prevalence of self-
reported cataract was higher for all dosages of GCS, 
whereas the prevalence of self-reported glaucoma was 
only increased in those taking > 7.5 mg/day (6.6% users 
vs. 2.7% non-users).
7. Infections
A meta-analysis of randomised controlled clinical tri-
als in which patients were randomised to treatment 
with or without systemic GCS (n = 4198) showed that 
the rate of infection was not significantly increased 
in patients who were given a mean dose of less than 
10  mg/day of prednisone or a cumulative dose of less 
than 700 mg [117]. This meta-analysis included a wide 
variety of diseases warranting systemic GCS. The true 
risk of developing infection in patients using short 
courses for upper airway disease remains uncertain.
8. Local adverse effects of steroid‑injections
We found one case report on gluteal subcutaneous 
atrophy that was seen after a depot steroid injection of 
triamcinolone for AR [118]. A study of Laursen et  al. 
[34] investigated specifically the reporting of all AE’s 
related to GCS injections for AR to the ‘Danish Reg-
ister for the Side-Effects of Drugs’ and evaluated the 
reported events consecutively for a 10-year period. The 
study demonstrated that one out of 11,785 injections 
came with any local AE. Most AE’s were reversible and 
primarily skin related, such as skin atrophy.
9. Cardiovascular adverse effects
Cardiovascular disease is mainly associated with high 
dose and long-term use, primarily hypertension and 
acute myocardial infarction are described [100, 119].
A population-based cohort study in 68,781 GCS 
users and 82,202 non-users showed that patients 
exposed to dosages of GCS > 7.5  mg of prednisolone/
day (or equivalent) during 1 to 5  years of follow-up, 
had substantially higher rates of myocardial infarction, 
heart failure, or cerebrovascular disease (adjusted RR 
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of 2.56; 95% CI 2.18–2.99). The risk was not increased 
in patients using < 7.5  mg prednisolone equivalent 
daily [120].
Another large, retrospective case–control study with 
data extracted from the General Practice Research 
Database (1988–1997) showed in over 100,000 indi-
viduals that the use of oral GCS comes with a 25% 
higher risk of any cardiovascular or cerebrovascular 
outcome compared to controls. Current use (in the 
3 months before the registration of an event) and high-
est average daily dose give a much stronger associa-
tion. Current use is also associated with a significantly 
increased risk of heart failure (adjusted OR of 2.66; 95% 
CI 2.46–2.87) and ischemic heart disease (OR of 1.20; 
95% CI 1.11–1.29), but not ischemic stroke or transient 
ischemic attack. Cardiovascular risk showed a clear 
dose–response relationship [121].
To our knowledge, the risk in patients using GCS for 
intermittent short courses is unknown.
10. Neuropsychiatric effects
A study from Hissaria et  al. [60] investigating 40 
CRSwNP patients treated with 50  mg of prednisolone 
daily for 14  days or placebo, found that sleep distur-
bances were reported as a significant prevalent AE 
(40%) compared to placebo (10%). Mood disturbance 
were more frequently reported, but not significantly 
different from placebo (25% vs. 10%).
In the above-mentioned controlled trial by Venekamp 
et  al. [41] studying ARS patients treated with 30  mg/
day prednisolone or placebo for 7 days, the incidence of 
mood or sleep disturbance did not differ between treat-
ment groups.
Two studies in asthmatic and ophthalmologic patients 
receiving short-courses of GCS, showed a development 
of (hypo)mania [122, 123] as well as depression symp-
toms [123].
Naber et  al. [123] showed in a prospective uncon-
trolled study in ophthalmologic patients receiving 
systemic GCS (n = 50) that 26–34% of patients devel-
oped (hypo)mania and 10–12% developed depres-
sion syndromes when using an initial 119 ± 41  mg/
day MP or fluorcortolone, tapered to 75 ± 22  mg/day 
at 8 days. The onset of symptoms was within 3 days of 
use and there was no correlation between daily dose 
and daily ratings of mood. Brown et  al. [122] showed 
in 32 asthmatic patients using prednisone (mean course 
13.9  days, mean dose of 36.9  mg/day) a highly signifi-
cant increase in self-reported mania, but no increase in 
depression during the first 3–7  days of therapy. Mood 
changes returned back to normal after discontinuation 
of therapy.
11. Cushingoid features
We found no studies investigating Cushingoid appear-
ance in rhinitis/rhinosinusitis patients treated with GCS 
and only a few studies addressed the risk of intermittent 
short courses of GCS and weight gain.
A randomised controlled trial by Campieri et al. [124] 
in patients with active Crohn’s disease demonstrated that 
38% of patients on a regimen of prednisolone tapered 
over 12 weeks (40–45 mg) developed a ‘moon face’. Mean 
body weight increased with 2.1 kg after 8 weeks of treat-
ment. Bar-Meir et al. [125] showed that patients receiv-
ing 8 weeks of prednisone developed a moon face in 33% 
versus 16% in patients receiving a similar treatment with 
budesonide.
Benefit and risk of use of GCS in pediatric 
populations
Inflammatory diseases of the nose and paranasal sinuses 
in children include upper respiratory tract infec-
tions, chronic rhinitis, ARS and CRS. ARS is defined as 
increase of sinonasal symptoms after 5 days of infection 
or persistent symptoms after 10  days and characterized 
by the sudden onset of two or more of the symptoms 
(discoloured nasal discharge, nasal blockage/obstruction/
congestion, cough at daytime and night-time) for less 
than 12  weeks [4]. Bacterial infection is expected when 
at least 3 symptoms are present among which discol-
oured discharge, purulent secretion in nasal cavity, severe 
local pain with a unilateral predominance, fever, elevated 
C-reactive protein or erythrocyte sedimentation rate, and 
double sickening (i.e. deterioration after an initial milder 
phase of illness) [4]. The definition of pediatric CRS dif-
fers from adult CRS by the symptom of cough [4] and is 
defined by the presence of two or more symptoms, one 
of which should be either nasal obstruction or nasal dis-
charge (anterior or posterior) with/without facial pain/
pressure with/without cough, lasting for at least 12 weeks 
[4]. The diagnosis is confirmed by either nasal endoscopy 
showing edema, purulent drainage or nasal polyps in the 
middle meatus or CT scan showing ostiomeatal complex 
or sinus opacification. Of note, the presence of nasal pol-
yps is much less common in pediatric patients than in 
adult patients with CRS [126].
1. Efficacy of systemic GCS in pediatric CRS and ARS
Three clinical trials can be found in literature that inves-
tigated the use of oral GCS in the pediatric rhinosinusitis 
population, of which only one is controlled (Table 10).
This controlled study involved 48 children (mean 
age 8  years) with CRSsNP [66] and investigated the 
effect of oral GCS as an add-on to antibiotics. 22 
participants received either 30-day course of oral 
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amoxicillin–clavulanate and 15-day course of oral MP 
and 23 participants received only antibiotics and a pla-
cebo. The mean change of total symptom score and CT 
score was significantly higher after treatment with oral 
GCS and antibiotics compared with placebo and anti-
biotics (P < 0.001). There was also a significant benefi-
cial effect of oral GCS in cough, nasal obstruction and 
post-nasal drainage symptom scores. Complete clinical 
recovery after 30 days of treatment was obtained in sig-
nificantly more subjects receiving MP (P < 0.005). Recur-
rence of symptoms 6 months after the end of treatment 
was not statistically significant between the groups.
Additionally, a retrospective study involving 35 young 
CRS patients (1–21  years) undergoing serial sinus CT 
scans due to medical reasons, evaluated Lund Mackay 
ostiomeatal complex score in relation to three different 
treatment schemes [127] antibiotics, intranasal topical 
GCS and oral systemic GCS. The data suggested that the 
use of systemic GCS was associated with a significant 
increase in the likelihood of radiologic improvement. The 
retrospective study design, the small and heterogeneous 
population, heterogeneous treatment modalities, and the 
lack of adjustments, limit the possibilities to assess clini-
cal significance of the findings.
A second uncontrolled study [5] evaluated cytokine 
pattern of 30 asthmatic CRS patients (4–12 years) before 
and after the treatment of amoxicillin–clavulanate, flu-
ticasone propionate aqueous nasal spray and a short 
course of oral deflazacort. After the treatment, endo-
scopic resolving of mucopurulent discharge was detected 
in 25/30 children, the median concentration of IL-4 
decreased significantly in all subjects, and the median 
IFN-γ concentration increased significantly only in the 
atopic subgroup (N = 16). The uncontrolled study design 
and uncertainty whether the patients used prescribed 
drugs, limits the possibilities to assess effect of systemic 
GCS.
2. Harm of GCS in children
There is limited knowledge of risks of using systemic 
GCS in pediatric CRS or ARS compared to pediatric 
asthma. As an example, the Childhood Asthma Manage-
ment Program trial followed the annual bone mineral 
accretion of 877 children (5–12  years) with mild-to-
moderate asthma [128, 129]. Oral GCS bursts produced 
a dosage-dependent reduction in bone mineral accretion 
(0.052, 0.049, and 0.046 g/cm2 per year) and an increase 
in risk for osteopenia (10%, 14%, and 21%) for 0, 1–4, and 
≥ 5 courses, respectively, in boys. The authors conclude 
that multiple oral GCS bursts over a period of years can 
produce a dosage-dependent reduction in bone mineral 
accretion and increased risk for osteopenia in children 
with asthma. 780 children with asthma were followed for 
a mean of 4.3 years and it was shown that boys with lower 
vitamin D levels are significantly more susceptible to the 
negative effects of GCS on bone mineral accretion over 
time [129]. Regarding studies investigating GCS AE’s in 
upper airway disease, the trial from Ozturk also looked 
at self-reported AE’s during the 15-day course of oral 
MP [66]. In this trial no clinically significant AE’s were 
reported. At the end of the treatment, the mean weight 
change did not differ statistically significantly between 
the groups. No data of monitored AE’s, nor that of long-
term outcomes, nor that of bacterial culture were avail-
able in this study.
A systematic review has been performed to determine 
the most common and serious drug-related AE of long 
courses of oral GCS in children [130]. Literature search 
of several databases was performed to identify all studies 
in which systemic GCS had been administered to pedi-
atric patients ranging from 28 days to 18 years of age for 
at least 15 days of treatment. The group found 91 studies 
that represented a total of 6653 children and contained 
reports of 4124 adverse drug reactions, the majority in 
patients with leukaemia, haemangioma and asthma. The 
three most frequent adverse drug reactions were weight 
gain (22.4%), Cushingoid features (20.6%) and growth 
retardation (18.9%). Increased susceptibility to infection 
was the most serious adverse drug reaction. 24 children 
died from infections, 10 from varicella zoster.
There is insufficient knowledge of the effect and harm 
of short-term systemic GCS courses in pediatric CRS 
patients. However, based on studies on pediatric asthma, 
a single short-term systemic GCS course could be con-
sidered in pediatric patients suffering from CRS that 
is not responding to other therapies such as intranasal 
GCS, antibiotics, supporting therapy (saline douchings, 
decongestants) and adenoidectomy. It is mandatory to 
perform more powered; randomized placebo-controlled 
clinical trials of pediatric ARS and CRS with long-term 
follow up and report of AE’s.
• Evidence level: B.
• Benefits–harm assessment: AE’s of systemic GCS 
outweigh advantages of therapeutic value in mild and 
moderate disease.
• Recommendation: Strong recommendation against. 
Option in patients suffering from very severe and 
therapy-resistant disease, in combination with antibi-
otics.
Health economic considerations related to GCS use
Besides clinical consequences, systemic GCS use may 
also have some health economic implications that should 
be considered in its benefit-harm trade-off. Generally, 
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the direct costs for systemic GCS are among the low-
est quartile of prices of medications available world-
wide. However, the indirect costs due to adverse events 
of (especially long-term, high-dose) systemic GCS use 
could be more substantial. Two industry-funded studies 
have assessed the cumulative economic burden of GCS 
associated adverse events regardless of dose, duration or 
indication [131, 132]. Manson et  al. [131] identified 63 
studies in which 21 different GCS adverse events were 
reported with increased fracture risk, gastric and psy-
chiatric conditions being the most frequent ones. Their 
economic analysis from the UK perspective revealed that 
taking oral GCS would result in an additional annual cost 
of at least £165 for treatment of all steroid related adverse 
events. One study specifically assessed the economic 
impact of oral GCS on related fractures where hip, ver-
tebral and forearm fractures costed £10,761, £1976 and 
£863 respectively. Notably, only three studies focused 
on patients with allergic rhinitis and/or skin diseases 
and none specifically on rhinosinusitis. A second review 
[132] included 47 studies reporting on adverse events of 
systemic GCS. Subsequently, a cost analysis was under-
taken from the US perspective. It was unclear whether 
any patients with allergic rhinitis or rhinosinusitis were 
included. Most frequently reported adverse events were 
psychiatric and gastric conditions, infections and frac-
tures. The authors estimated the potential cost reduc-
tions if the daily GCS dose would be reduced. Regarding 
avoidance of fractures, they estimated that 96 fractures 
per 10,000 elderly patients could be avoided summing 
up to $1.76 million ($176 per patient). The findings from 
both reviews should be interpreted with caution given 
the heterogeneous and often low-quality and retrospec-
tive nature of the studies included and the difficulty in 
excluding confounding due to underlying disease activ-
ity. Besides these two reviews with no particular disease 
focus, some studies focused on the costs of systemic GCS 
related adverse events within a specific population such 
as asthma [133, 134] or rheumatologic diseases [135, 136] 
and found increased costs in the GCS exposed popula-
tions. None were specifically focusing on rhinitis or rhi-
nosinusitis. We conclude that given the limited amount 
of current evidence, more studies on the economic bur-
den and cost-effectiveness of systemic GCS use in rhinitis 
and rhinosinusitis treatment are required.
Alternatives for GCS in upper airway disease
In both rhinitis and rhinosinusitis patients, systemic 
GCS treatment is in general reserved for those in whom 
disease control cannot be obtained by baseline medi-
cal therapy (intranasal steroids and antihistamine/anti-
leukotrienes for AR [30] and intranasal steroids and 
antibiotics for ARS/CRS [4]). However, in AR, allergen 
immunotherapy (AIT) is an alternative option for patients 
suffering from uncontrolled symptoms. AIT modifies the 
natural disease course and recent well-performed trials 
have demonstrated reductions in both symptoms and 
use of rescue medication in patients with AR for both 
the subcutaneous as well as sublingual administration 
route [137]. One study from 1969 compared the efficacy 
of one depot MP injection with a pre-seasonal adminis-
tration of an alum-precipitated pyridine extracted grass 
pollen immunotherapy and found similar results between 
the two groups in terms of symptom improvement [138]. 
However, this paper already stated that the potential AE’s 
of MP do not justify the use of systemic GCS for a condi-
tion such as AR. One large Danish registry study includ-
ing almost 40,000 AR patients actually showed the oral 
steroid-sparing effect of subcutaneous AIT (SCIT) for 
seasonal AR with an annual mean of 1.0 steroid injections 
in patients receiving SCIT versus a mean of 1.6 injections 
in the non-SCIT group. Of the SCIT-treated individuals, 
84% did not need GCS at all after SCIT treatment [139]. 
Aasbjerg looked at the same registry to compare AE’s and 
found that AR patient treated with systemic GCS showed 
more diabetes and osteoporosis than those treated with 
AIT as mentioned above [107].
For CRS patients, current alternatives for oral GCS 
during exacerbations consist of antibiotics and when 
patients remain uncontrolled, sinus surgery is the next 
step in line [4]. However, studies investigating biologi-
cal agents that are available for the treatment of asthma 
and/or other allergic diseases, have shown very beneficial 
effects in CRSwNP patients [140] but are currently only 
available for those with severe concomitant asthma.
Gevaert et al. [141] extrapolated results from different 
studies to compare the efficacy of different treatments in 
CRSwNP patients. They found a beneficial effect on NP 
score of doxycycline that was comparable to MP after 
8  weeks. Also, omalizumab and mepolizumab treat-
ment had better results on NP score than the oral GCS 
treatment. Omalizumab and mepolizumab addition-
ally showed better symptom control compared to MP. 
Currently only data on the oral steroid-sparing effects 
of mepolizumab and benralizumab in asthma are avail-
able [142], but with the increased implementation of 
these therapies in CRSwNP, studies evaluating the ster-
oid-sparing effect for upper airway exacerbations will be 
necessary.
Conclusion
When disease control in upper airway disease cannot 
be obtained with intranasal steroids or other medi-
cal treatment prescribed by the respective guidelines, 
severe cases of AR, ARS, AFRS and CRSwNP can be 
treated with a short-term course of systemic GCS to 
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improve symptoms. This manuscript provided an over-
view of the current evidence for the beneficial effects 
of systemic GCS in the different subtypes of upper air-
way diseases, as well as in the pediatric age group and 
aimed at providing recommendations for the specific 
disease entities.
However, multiple AEs have been widely described 
and therefore physicians should be aware of the risks 
associated with oral GCS and make a good risk–ben-
efit assessment prior to prescribing them. In this paper, 
we summarize these potential AEs; given the current 
evidence in literature, a clear assessment of the risks 
associated with oral steroid use in upper airway dis-
ease cannot be made. Currently available data show a 
wide variability in diseases, patients, duration of treat-
ment and follow-up and therefore this topic needs to 
be addressed in a systematic way in order to provide a 
substantiated recommendation for the use and dosing 
of oral GCS in the upper airway disease population.
We can conclude that, although some beneficial 
effects of systemic GCS have been demonstrated in 
chronic upper airway diseases such as AR and CRSwNP, 
systemic GCS should not be considered as a first line of 
treatment for these disease types.
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